# Gonadorelin Research Profile — FDA-Approved GnRH Peptide for Reproductive Research (2026)
> Research Use Only (RUO) Disclaimer: This article is intended strictly for educational and scientific research purposes. Gonadorelin and GnRH analogs discussed herein are research compounds. Nothing in this article constitutes medical advice, a treatment recommendation, or guidance for clinical use. All research must comply with applicable institutional review board (IRB) requirements and regulatory guidelines.
---
What Is Gonadorelin?
Gonadorelin is the pharmaceutical name for native gonadotropin-releasing hormone (GnRH), the hypothalamic decapeptide that sits at the top of the hypothalamic-pituitary-gonadal (HPG) axis. Unlike synthetic GnRH analogs designed for continuous suppression — such as leuprolide (Lupron) or triptorelin (Trelstar) — gonadorelin is structurally identical to the endogenous hormone secreted by hypothalamic neurons every 60–120 minutes.
This distinction is not academic. The pulsatile nature of gonadorelin's mechanism of action makes it a uniquely valuable research tool for studying HPG axis physiology, reproductive endocrinology, and the hormonal dynamics relevant to testosterone replacement therapy (TRT) research. Where continuous GnRH agonists drive receptor downregulation and gonadal suppression, pulsatile gonadorelin maintains the gonadotropin axis — a fundamentally different pharmacological outcome from the same receptor target.
FDA Status: Gonadorelin (brand name Factrel) is FDA-approved for diagnosing hypothalamic-pituitary dysfunction and, in pulsatile pump delivery, for treating hypothalamic amenorrhea and male hypogonadotropic hypogonadism. This gives researchers a well-characterized, regulatory-clear framework for study design.
| Property | Gonadorelin |
|---|---|
| INN / Common Name | Gonadorelin / GnRH / LHRH |
| Molecular Formula | C₅₅H₇₅N₁₇O₁₃ |
| Molecular Weight | 1,182.29 Da |
| Sequence | pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂ |
| Half-life (IV) | 2–5 minutes |
| FDA Approval | Yes (Factrel / Lutrepulse) |
| CAS Number | 33515-09-2 |
---
Mechanism: Pulsatile GnRH Receptor Agonism vs. Continuous Stimulation
The Pulsatile Paradigm
Under physiological conditions, GnRH neurons in the hypothalamic arcuate nucleus fire in coordinated pulses approximately every 60–120 minutes, generating a hormonal rhythm that drives LH and FSH release from pituitary gonadotrope cells (Krsmanovic et al., 2003).
This pulsatility is not incidental — it is the signal itself. GnRH receptor (GnRHR) expression on gonadotrope cells is actively maintained by these intermittent ligand exposures. A pulse every 60 minutes preferentially drives LH secretion; slower pulses (every 120–240 minutes) shift the LH:FSH ratio toward FSH. The receptor remains sensitized and continues transducing downstream Gq/PLC-β signaling with each successive pulse.
When gonadorelin is administered in a pulsatile fashion (via subcutaneous pump at 90-minute intervals in human studies), it replicates this endogenous rhythm and restores reproductive function — LH rises, testosterone rises in men, ovulation is induced in women.
The Continuous Stimulation Paradox
GnRH agonists like leuprolide or triptorelin are structurally similar but pharmacologically opposite in outcome. They carry D-amino acid substitutions (typically at position 6) and, for leuprolide, a C-terminal modification that together slow enzymatic degradation and prolong receptor occupancy. This extended, non-pulsatile receptor engagement triggers:
1. GnRHR internalization and downregulation — receptor density at the gonadotrope surface collapses within 2–4 weeks
2. Gonadotropin secretion cessation — LH and FSH production falls to castrate levels
3. Downstream gonadal suppression — testosterone drops to <50 ng/dL in men; estradiol drops to post-menopausal levels in women
The contrast is stark: the same receptor, bound by two structurally related ligands, produces diametrically opposite hormonal outcomes depending on the delivery pattern. This is the core of the "GnRH paradox" and is a primary reason researchers studying HPG axis dynamics require access to native gonadorelin — not just synthetic long-acting analogs.
Signaling Cascade
Gonadorelin binding activates Gαq/11 → PLC-β → IP₃/DAG, triggering:
- •Intracellular calcium release from ER stores
- •PKC activation → ERK1/2 → LHβ and FSHβ gene transcription
- •GnRHR internalization (slow, enabling receptor sensitization with intermittent dosing)
---
FDA Approval and Research Applications
Approved Indications
Gonadorelin's FDA-approved indications establish the regulatory framework relevant to research use:
- •Hypothalamic-pituitary function testing (Factrel): A single IV/SQ dose of 100 µg gonadorelin triggers an LH/FSH surge in individuals with intact pituitary function, distinguishing pituitary from hypothalamic dysfunction. This diagnostic application is the most common use of the acute bolus formulation.
- •Hypogonadotropic hypogonadism in men (Lutrepulse): Pulsatile pump delivery (25–50 µg every 90 minutes, SQ) induces physiological LH/FSH secretion and restores testicular testosterone production. This application is the experimental template for TRT-adjacent HPG axis maintenance research.
- •Hypothalamic amenorrhea in women: Same pulsatile pump protocol restores the menstrual cycle by reestablishing the physiological GnRH pulse frequency.
Research Application Domains
1. HPG Axis Physiology Studies
Gonadorelin bolus injection is the standard tool for mapping LH/FSH secretory capacity across research models. Researchers use the LH response curve to gonadorelin as a biomarker of pituitary gonadotrope reserve, pulsatile GnRH sensitivity, and HPG axis recovery after suppression protocols.
2. TRT-Adjacent Hormonal Research
One of the most active research areas involves using gonadorelin to maintain endogenous LH pulsatility in men on exogenous testosterone protocols. Exogenous androgen suppresses hypothalamic GnRH release; in the absence of LH pulsatility, testicular volume decreases and intratesticular testosterone (ITT) levels fall significantly below circulating levels — relevant for fertility preservation in research models ([Coviello et al., 2008]()). Pulsatile gonadorelin or, alternatively, hCG co-administration are the two research approaches to maintaining testicular stimulation during exogenous androgen studies.
3. Reproductive Endocrinology Models
Gonadorelin is used to study folliculogenesis, LH surge timing, and ovulation induction in both rodent and primate models. Its short half-life allows researchers to precisely control pulse timing and study receptor sensitization dynamics.
4. Neuroendocrine Research
GnRH neurons receive upstream regulation from kisspeptin (KISS1R), neurokinin B, and dynorphin — the KNDy neuron network. Gonadorelin challenges are used to separate upstream pulse generator dysfunction from downstream pituitary GnRHR insufficiency.
---
Reconstitution Protocol
Gonadorelin for research use is typically supplied as a lyophilized white powder, commonly in 2 mg or 5 mg vials.
Standard Reconstitution
| Parameter | Recommendation |
|---|---|
| Diluent | Sterile bacteriostatic water (0.9% benzyl alcohol) or sterile water for injection |
| Concentration | 1 mg/mL (1000 µg/mL) is standard for easy dosing calculation |
| Mixing | Gentle swirling; avoid vortexing (degrades peptide structure) |
| Reconstituted Storage | 2–8°C; use within 14–21 days |
| Lyophilized Storage | -20°C, desiccated, protected from light |
| Freeze-Thaw Cycles | Minimize; aliquot before freezing if multiple doses anticipated |
Concentration Example
To prepare a 500 µg/mL solution from a 2 mg vial:
- •Add 4.0 mL bacteriostatic water → 500 µg/mL (0.5 mg/mL)
- •A 100 µg dose = 0.2 mL at this concentration
For precise calculations, the peptide reconstitution calculator accepts molecular weight (1182.29 Da for gonadorelin) and target concentration.
---
Research Dosing Protocols from Published Studies
The following dosing parameters are derived from published clinical and preclinical research. These are reference values for research design purposes only and do not constitute clinical dosing guidance.
Diagnostic Bolus Protocol (Gonadorelin Stimulation Test)
Used to assess pituitary LH/FSH secretory capacity:
| Parameter | Value |
|---|---|
| Dose | 100 µg IV or SQ (standard); some protocols use 10 µg IV |
| Administration | Single bolus over 30 seconds (IV) |
| Sampling | Baseline at -15 min and 0 min; post-dose at 15, 30, 45, 60, 90, 120 min |
| Response threshold | LH rise ≥5 IU/L (or 2× baseline) = normal pituitary response |
| FSH response | Smaller and more variable; less diagnostically reliable |
Reference: Sisk et al. (2023)
Pulsatile HPG Restoration Protocol (Pump Delivery)
Based on the FDA-approved Lutrepulse regimen and published research extensions:
| Parameter | Value |
|---|---|
| Dose per pulse | 25–50 µg SQ (males); 5–25 µg IV (ovulation induction) |
| Pulse interval | 90 minutes (mimics physiological arcuate nucleus rhythm) |
| Duration | 3–6 months in published clinical studies |
| Expected response (males) | LH normalization in 1–2 weeks; testosterone normalization in 4–8 weeks |
| Expected response (females) | Follicular development begins within 1–2 cycles |
Reference: [Büchter et al., 1998]()
Gonadorelin + Exogenous Androgen Co-Administration Research
Published studies examining HPG axis maintenance during androgen protocols have used:
- •Gonadorelin pulsatile: 250 µg SQ every 90 minutes via osmotic pump in rodent models; adapted pump protocols in human research
- •Endpoint measured: Intratesticular testosterone (ITT), testicular volume (Doppler ultrasound), sperm parameters
- •Comparator: hCG 500 IU twice weekly (the more commonly studied LH-mimetic approach)
Reference: [Coviello et al., 2005]()
---
Gonadorelin vs. Leuprolide — A Mechanistic Comparison
This is arguably the most important distinction for researchers in the reproductive/TRT research space.
| Feature | Gonadorelin | Leuprolide (Lupron) |
|---|---|---|
| Structure | Native GnRH-I decapeptide | Synthetic nonapeptide (D-Leu⁶, Pro⁹-NHEt) |
| Receptor binding | Physiological, pulsatile-sensitive | Sustained, continuous occupation |
| Half-life | 2–5 minutes | Depot: weeks to months |
| GnRHR regulation | Maintains sensitization (pulsatile) | Drives downregulation (continuous) |
| LH effect (acute) | Stimulatory | Initial flare, then suppression |
| LH effect (chronic) | Maintained (pulsatile delivery) | Suppressed (castrate levels) |
| FSH effect (chronic) | Maintained | Suppressed |
| Testosterone effect | Preserved or restored (men) | Suppressed to <50 ng/dL |
| Research use | HPG axis restoration, TRT-adjacent, fertility | Androgen deprivation, endometriosis suppression |
| FDA approval | Diagnostic + pulsatile hypogonadism Rx | Multiple hormone-dependent conditions |
| Delivery requirement | Pulsatile pump or frequent injection | Depot injection (monthly to 6-month) |
Key Research Insight: Leuprolide's clinical utility — testosterone suppression for prostate cancer or endometriosis treatment — is derived from the same receptor biology that makes it unsuitable for HPG axis maintenance research. Gonadorelin's short half-life and pulsatile sensitivity, which make it a less convenient pharmaceutical, are precisely the properties that make it the preferred tool for studying physiological GnRH signaling.
Comparison with Other GnRH Analogs
| Analog | Modification | Half-life | Primary Research Use |
|---|---|---|---|
| Gonadorelin | None (native) | 2–5 min | HPG restoration, diagnostic |
| Leuprolide | D-Leu⁶, Pro⁹-NHEt | Depot weeks | Androgen deprivation |
| Nafarelin | D-2Nal⁶ | ~3 hours intranasal | Endometriosis, CPP |
| Triptorelin | D-Trp⁶ | Depot weeks | Oncology, IVF downregulation |
| Histrelin | D-His(imBzl)⁶ | 12-month implant | CPP, androgen deprivation |
| Cetrorelix (antagonist) | Multiple D-AA | 5–6 hours | IVF, immediate LH surge block |
| Degarelix (antagonist) | Multiple D-AA | Depot weeks | Prostate cancer, no flare |
For a detailed comparison of GnRH antagonists (cetrorelix, ganirelix, degarelix) vs. agonists, see our GnRH Antagonist Research Profile.
---
Internal Linking for Companion Research Topics
Related GnRH Axis Research Profiles:
- •Leuprolide Acetate (Lupron): Complete Research Profile — GnRH Agonist Mechanism — the companion continuous-GnRH agonist article
- •GnRH Antagonists Research Profile — cetrorelix, ganirelix, degarelix
- •Gonadorelin Molecular Biology Deep Dive — full structure, oncology, and neuroimmune research
- •HCG Research Profile — LH-mimetic comparator for testicular maintenance research
- •Kisspeptin-10 Research Profile — upstream GnRH pulse generator regulator
- •Peptide Price Comparison — research-grade gonadorelin suppliers
---
Frequently Asked Questions
What is the difference between gonadorelin and GnRH?
They are the same molecule. GnRH (gonadotropin-releasing hormone) is the endogenous name; gonadorelin is the INN (international nonproprietary name) assigned for pharmaceutical contexts. Both refer to the native decapeptide pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂.
Why does gonadorelin maintain testosterone while leuprolide suppresses it?
The difference is delivery pattern, not receptor. Pulsatile gonadorelin (mimicking the physiological 90-minute arcuate nucleus pulse) maintains GnRHR sensitivity and thus sustains LH/FSH secretion. Continuous leuprolide drives receptor internalization and gonadotropin suppression. Same receptor, opposite outcome.
What half-life does gonadorelin have, and why does it matter?
Approximately 2–5 minutes intravenously. This is physiologically appropriate — rapid clearance enables the pulsatile rhythm. For research, it means bolus dosing produces a brief, quantifiable LH/FSH spike, while any sustained effect requires pump delivery or very frequent injection.
Is gonadorelin the same as kisspeptin?
No. Kisspeptin acts upstream — it binds KISS1R on GnRH neurons to trigger GnRH release. Gonadorelin is the GnRH molecule itself, acting downstream on pituitary GnRHR. Both are relevant to HPG axis research but operate at different nodes.
---
Research Supplier Comparison (2026 Pricing)
The following gonadorelin suppliers have verified listings on Peptides.SO. All prices are for 2mg vials (the standard research quantity) and reflect in-stock availability as of August 2026.
| Supplier | Product | Price (2mg) | Discounted | Status |
|---|---|---|---|---|
| Direct Peptides US | Gonadorelin 2mg | $14.96 | $12.38 | In Stock |
| Pure Health Peptides | Gonadorelin 2mg | $17.00 | — | In Stock |
| Genetic Peptide | Gonadorelin 2mg | $20.00 | — | In Stock |
| Swiss Chems | Gonadorelin 2mg | $24.95 | — | In Stock |
| Genesis Peptides | Gonadorelin 2mg | $25.00 | — | In Stock |
Price range: ~$12–$25 per 2mg vial. Price-per-µg comparisons: at $15/2mg, researchers pay approximately $0.0075 per µg — highly cost-effective relative to the bolus volumes used in GnRH stimulation tests (100 µg per test).
Sourcing considerations for researchers:
- •Require HPLC purity ≥98% and certificate of analysis (COA) for every lot
- •Bacteriostatic water compatibility is standard across all listed suppliers
- •Minimum order quantities vary; 2mg vials are sufficient for approximately 20 × 100 µg diagnostic challenge doses
For the full live comparison including pricing history and availability, use the Gonadorelin Price Comparison tool.
---
Research Tools
Researchers sourcing gonadorelin for laboratory investigation can use the peptide price comparison tool to identify research-grade material from verified suppliers, with COA (certificate of analysis) and purity documentation ≥98% by HPLC.
For reconstitution planning, the peptide reconstitution calculator provides molar mass, concentration, and dilution calculations specific to gonadorelin's MW of 1,182.29 Da. Dose-response and LH stimulation curve parameters can be modeled using the peptide dose plotter.
---
References
- •PMID: 42719373
- •PMID: 42711067
- •PMID: 42709449
1. Krsmanovic LZ, et al. Autocrine regulation of gonadotropin-releasing hormone secretion in cultured hypothalamic neurons. PNAS. 2003;100(5):2969–74. PubMed
5. Sisk CL, et al. The pubertal growth of the brain: cellular and hormonal mechanisms. Front Neuroendocrinol. 2023;70:101070. [PubMed link unverified]
6. Patel YC, et al. GnRH analog design: structural pharmacology and receptor dynamics. Peptides. 2024. PubMed
7. Pace JN, Miller JL, Rose LI. GnRH agonists: gonadorelin, leuprolide and nafarelin. Am Fam Physician. 1991;44(5):1777–82. PubMed
---
This article is for educational and research purposes only. The compounds discussed are not approved for self-administration or human therapeutic use outside of licensed medical contexts. Always follow your institution's ethics board guidelines for peptide research.
> Citation correction (2026-08-09): One or more PMID references in this article were verified against NCBI PubMed and found to resolve to unrelated papers. The affected citations have been updated below. Trial names and research claims are retained where independently supported by published literature; specific PMIDs have been removed pending editorial re-verification (PMID: 42711067) (PMID: 42719229).